Anti-PD-1 therapy can lengthen both PFS and OS in advanced melanoma patients as a first-line drug recommended by the NCCN guidelines, whose clinical performance is superior to anti-CTLA-4 therapy (29). This evidence concerns the gene PDCD1 and melanoma.